|1.||Lamont, Ronald F: 4 articles (01/2010 - 01/2003)|
|2.||Flenady, Vicki: 3 articles (01/2014 - 01/2009)|
|3.||Akerlund, Mats: 3 articles (01/2006 - 01/2002)|
|4.||Papatsonis, Dimitri N M: 2 articles (01/2014 - 01/2013)|
|5.||Liley, Helen G: 2 articles (01/2014 - 01/2013)|
|6.||Hadar, Eran: 2 articles (10/2013 - 06/2011)|
|7.||Wilczynski, Jan: 2 articles (01/2013 - 01/2013)|
|8.||Grzesiak, Mariusz: 2 articles (01/2013 - 01/2013)|
|9.||Wex, Jaro: 2 articles (08/2011 - 01/2009)|
|10.||Mohammadghasemi, Fahimeh: 2 articles (02/2011 - 07/2010)|
|1.||Premature Obstetric Labor (Premature Labor)
01/01/1998 - "Goodwin et al compared the effect of Atosiban to placebo in threatening preterm labor and the antagonist was in this trial significantly more effective than placebo in reducing the frequency of contractions (55% vs. 23%, p < 0.001). "
01/01/2007 - "To compare the efficacy of atosiban with usual management of threatened preterm labor. "
10/01/2001 - "This study supports the clinical use of atosiban in the treatment of preterm labor."
05/01/2000 - "A multicenter, double-blind, placebo-controlled trial was designed for patients in preterm labor who responded to early intravenous treatment with atosiban. "
05/01/2000 - "This study was designed to compare the efficacy and safety of atosiban with those of placebo maintenance therapy in women with preterm labor who achieved uterine quiescence with intravenous atosiban. "
|2.||Premature Birth (Birth, Premature)
12/01/2004 - "Atosiban is a newer agent, which appears to be effective in delaying preterm birth with a favourable maternal safety profile, but there are persisting concerns about the lack of impact on perinatal mortality and morbidity. "
01/01/2014 - "In one study, atosiban resulted in an increase in extremely preterm birth (before 28 weeks' gestation) (RR 3.11, 95% CI 1.02 to 9.51; NNTH 31, 95% CI 8 to 3188) and infant deaths (up to 12 months) (RR 6.13, 95% CI 1.38 to 27.13; NNTH 28, 95% CI 6 to 377). "
01/01/2007 - "These findings support the use of atosiban to delay preterm birth and are consistent with previously conducted, randomized, controlled trials. "
04/01/2014 - "Currently, based on the evidence of safety and efficacy, atosiban should be the first-choice tocolytic for the treatment of SPTL to prevent or delay preterm birth."
01/01/2013 - "When compared with placebo, atosiban did not reduce preterm birth before 37 weeks (risk ratio (RR) 0.89; 95% confidence intervals (CI) 0.71 to 1.12), 32 weeks (RR 0.85; 95% CI 0.47 to 1.55), or 28 weeks (RR 0.75; 95% CI 0.28 to 2.01). "
10/01/2009 - "Fetal tachycardia was lower in the atosiban group (2% vs. 22%). "
02/01/2008 - "Maternal side effects were observed in 27.5% of cases of the atosiban group, none with tachycardia, dyspnea or tachypnea. "
07/01/2006 - "We conclude that atosiban is associated with a significantly lower incidence of maternal tachycardia and improved neonatal outcome compared with ritodrine."
06/01/2009 - "The present study showed similar effectiveness between atosiban and ritodrine, while tachycardia occurred more frequently in women treated with ritodrine. "
06/01/2009 - "There were no serious adverse events, but maternal cardiovascular adverse events, particularly tachycardia, occurred significantly more in women treated with ritodrine (0% atosiban vs. 18.18% ritodrine, p < 0.05). "
01/01/2008 - "Commentary: a case of non-cardiogenic lung edema in a woman treated with atosiban for preterm labor."
01/01/2008 - "Non-cardiogenic lung edema in a woman treated with atosiban for preterm labor."
02/25/2010 - "Oxytocin treatment decreased the exacerbated anxiety, MPO and MDA levels and inflammatory cell infiltration and submucosal edema while atosiban abolished all the protective effects of OT. "
|5.||Dysmenorrhea (Menstrual Pain)
01/01/2002 - "Atosiban and the non-peptide compound, SR 49059, which binds to the two receptors in a similar way as atosiban, are therapeutically effective in dysmenorrhea."
01/01/2000 - "Our results do not support the contention that vasopressin is involved in the etiology of dysmenorrhea, plasma concentrations of vasopressin being similar in dysmenorrheic women and controls, and the vasopressin antagonist Atosiban having no effect on menstrual pain, intrauterine pressure or uterine artery pulsatility index in dysmenorrheic women."
01/01/2000 - "We compared menstrual pain, uterine contractility and blood circulation, and plasma concentrations of vasopressin and prostaglandin F(2alpha) metabolite in women with versus without primary dysmenorrhea, and determined the effects of a vasopressin antagonist, 1-deamino-2-D-Tyr(OEt)-4-Thr-8-Orn-oxytocin (Atosiban), on these parameters. "
01/01/2006 - "Atosiban reduces vasopressin-induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea. "
01/01/2006 - "In subjects with dysmenorrhea the increase in pain following the administration of vasopressin was significantly lower during atosiban than during placebo infusion. "
|3.||Oxytocin Receptors (Oxytocin Receptor)
|7.||Adrenergic beta-Agonists (beta-Adrenergic Agonists)
|8.||Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)
|5.||Bed Rest (Bedrest)